Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 3, 2024Frontiers in PharmacologyOpen Access

Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system

View Full Paper
Ask AI
Bookmark
Share

Authors

KNKaibin NiuMFMaoxia FanWGWulin Gao

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Niu et al. (2024) studied this question.

synapsesocial.com/papers/68e665f2b6db6435875f2235https://doi.org/10.3389/fphar.2024.1414268
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 20232024 · 26 citations
  2. 2Pharmacovigilance of semaglutide: A descriptive analysis of WHO-VigiAccess reports2026 · 2 citations
  3. 3Semaglutide Exposure During Pregnancy: Results from the FAERS Database2026
  4. 42824-LB: Indication-Specific Adverse Event Profiles of Semaglutide and Liraglutide: A FAERS Disproportionality Analysis2026
  5. 5Retrospective Comparative Study of Oral Versus Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus2026